Pricing Log in Create free account

4D Molecular Therapeutics, Inc. (FDMT) vs Kura Oncology, Inc. (KURA)

4D Molecular Therapeutics, Inc. and Kura Oncology, Inc. are both Biotechnology companies. 4D Molecular Therapeutics, Inc. and Kura Oncology, Inc. are of similar size ($621.5M and $604.9M). 4D Molecular Therapeutics, Inc. has the higher net margin (−194.7% vs −384.3%) and the lower return on invested capital (−186.9% vs 0.00%). Across the 16 metrics below, 4D Molecular Therapeutics, Inc. leads on 11 and Kura Oncology, Inc. on 5.

Valuation

Metric FDMT KURA Biotechnology median
P/E n/m n/m 10.60
P/S 9.41 8.31 9.40
P/B 2.12 13.25 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 5.70 1.71 9.02
Earnings yield (22.38%) (46.68%) (32.88%)
Free cash flow yield (18.01%) (18.30%) (23.13%)

Profitability

Metric FDMT KURA Biotechnology median
Gross margin 100.00% 99.35% 68.51%
Operating margin (214.24%) (411.90%) 0.00%
Net margin (194.74%) (384.30%) 0.00%
Free cash flow margin (169.51%) (152.06%) 0.00%
Return on equity (43.25%) (167.71%) (51.96%)
Return on assets (37.09%) (46.73%) (46.06%)
Return on invested capital (186.91%) 0.00% 0.00%

Growth

Metric FDMT KURA Biotechnology median
Revenue growth (TTM) 278,712.12% — 6.76%
EPS growth (last fiscal year) 18.79% (57.43%) 29.88%
Revenue growth, 5-year CAGR 44.32% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FDMT KURA Biotechnology median
Debt to equity 0.05 0.20 0.00
Current ratio 8.03 4.73 4.97
Net debt to EBITDA 2.52 2.11 1.01

Dividend

Metric FDMT KURA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric FDMT KURA Biotechnology median
Market cap 621.50m 604.93m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack